FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2473105612> ?p ?o ?g. }

• W2473105612 endingPage "4127" @default.
• W2473105612 startingPage "4127" @default.
• W2473105612 abstract "Abstract Introduction Chronic lymphocytic leukemia (CLL) is typically diagnosed at an early stage and a watch & wait (W&W) strategy is applied. Only when the disease progresses to a more active, symptomatic form, treatment is indicated. The prospective CLL1 trial was designed to evaluate the benefit of early risk-adapted therapy with fludarabine (F) monotherapy, and to document the natural course of the disease from diagnosis. Here we present follow-up data to assess overall survival from the time point of treatment indication. Methods At enrolment, risk stratification was performed based on bone marrow (BM) infiltration pattern, lymphocyte doubling time (LDT), serum beta2-microglobulin (ß2-MG), and serum thymidine kinase (TK). Pts were “high-risk” (HR) if they had diffuse BM infiltration pattern and/or LDT<12 months (mo) combined with TK >7.0 U/L and/or ß2-MG >3.5 mg/L at enrolment. HR pts were randomized in a 1:1 ratio to early F (HR-F), or to W&W until classical treatment indication (HR-W&W), which was also applied to all low-risk (LR) pts. Results Between 1997 and 2004, 710 pts with Binet A stage CLL were enrolled and underwent risk stratification (RS) per protocol. Median time from diagnosis to enrolment was 3.2 mo (range 0-33.7) and median follow-up time was 8.5 years (yrs) (range 0-13.9). 521 pts (73%) were stratified to LR and 189 pts (27%) to HR, of whom 93 pts (49%) were randomized to HR-F and 96 pts (51%) to HR-W&W. Median age was 60 (range 32-75) yrs, 61% were male, 34% had unmutated IGHV status; high-risk cytogenetic features (17p- and 11q-) had 3% and 8% of pts, respectively. Early intervention with F among HR pts significantly prolonged progression-free survival (PFS) (30 vs. 13 mo; p<.001) and treatment-free survival (TFS) (74 vs. 41 mo; p=0.036) but did not significantly impact overall survival (OS) (127 mo vs. not reached; p=0.75). 303 patients had received treatment due to disease progression. 23% of patients received combination chemotherapy, 22% chemoimmunotherapy, 18% monotherapy with chlorambucil, and 15% monotherapy with purine analogues. Median OS for all pts was 91 mo (95% CI, 86 to 101 mo) from start of first treatment due to active disease. Patients with high risk (HR) for disease progression according to risk stratification had a significant shorter OS from start of first treatment than patients with low risk (LR) (71 mo vs. not reached; p=0.001). Early treatment with F did not show a significant impact on survival, when patients progressed after risk-adapted F, but showed a trend to a more favorable outcome for the watch and wait arm receiving their first therapy only when they had progressed to active disease (HR-F: median OS 51 mo versus HR-W&W not reached; p=0.055). Multivariate analyses on 237 pts identified 17p-, 11q-, unmutated IGHV, ß2-MG >3.5 mg/L, and age >60 yrs as independent prognostic factors for OS for patients with progressive, active disease and treatment indication. Conclusions Monotherapy with fludarabine is not superior to the W&W approach for the management of early stage CLL pts, since early F did not improve OS or outcome following subsequent therapies. Disclosures: No relevant conflicts of interest to declare." @default.
• W2473105612 created "2016-07-22" @default.
• W2473105612 creator A5016417334 @default.
• W2473105612 creator A5019866348 @default.
• W2473105612 creator A5021332351 @default.
• W2473105612 creator A5034222353 @default.
• W2473105612 creator A5052605376 @default.
• W2473105612 creator A5055431134 @default.
• W2473105612 creator A5061682665 @default.
• W2473105612 creator A5063616080 @default.
• W2473105612 creator A5064286825 @default.
• W2473105612 creator A5071376439 @default.
• W2473105612 creator A5075280681 @default.
• W2473105612 creator A5076077834 @default.
• W2473105612 creator A5077198246 @default.
• W2473105612 creator A5088826331 @default.
• W2473105612 creator A5089395073 @default.
• W2473105612 date "2013-11-15" @default.
• W2473105612 modified "2023-09-30" @default.
• W2473105612 title "Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)" @default.
• W2473105612 doi "https://doi.org/10.1182/blood.v122.21.4127.4127" @default.
• W2473105612 hasPublicationYear "2013" @default.
• W2473105612 type Work @default.
• W2473105612 sameAs 2473105612 @default.
• W2473105612 citedByCount "4" @default.
• W2473105612 countsByYear W24731056122015 @default.
• W2473105612 countsByYear W24731056122016 @default.
• W2473105612 countsByYear W24731056122017 @default.
• W2473105612 countsByYear W24731056122020 @default.
• W2473105612 crossrefType "journal-article" @default.
• W2473105612 hasAuthorship W2473105612A5016417334 @default.
• W2473105612 hasAuthorship W2473105612A5019866348 @default.
• W2473105612 hasAuthorship W2473105612A5021332351 @default.
• W2473105612 hasAuthorship W2473105612A5034222353 @default.
• W2473105612 hasAuthorship W2473105612A5052605376 @default.
• W2473105612 hasAuthorship W2473105612A5055431134 @default.
• W2473105612 hasAuthorship W2473105612A5061682665 @default.
• W2473105612 hasAuthorship W2473105612A5063616080 @default.
• W2473105612 hasAuthorship W2473105612A5064286825 @default.
• W2473105612 hasAuthorship W2473105612A5071376439 @default.
• W2473105612 hasAuthorship W2473105612A5075280681 @default.
• W2473105612 hasAuthorship W2473105612A5076077834 @default.
• W2473105612 hasAuthorship W2473105612A5077198246 @default.
• W2473105612 hasAuthorship W2473105612A5088826331 @default.
• W2473105612 hasAuthorship W2473105612A5089395073 @default.
• W2473105612 hasConcept C126322002 @default.
• W2473105612 hasConcept C141071460 @default.
• W2473105612 hasConcept C168563851 @default.
• W2473105612 hasConcept C203092338 @default.
• W2473105612 hasConcept C21957315 @default.
• W2473105612 hasConcept C2776694085 @default.
• W2473105612 hasConcept C2776755627 @default.
• W2473105612 hasConcept C2777938653 @default.
• W2473105612 hasConcept C2778461978 @default.
• W2473105612 hasConcept C2779263901 @default.
• W2473105612 hasConcept C2779709957 @default.
• W2473105612 hasConcept C71924100 @default.
• W2473105612 hasConcept C90924648 @default.
• W2473105612 hasConceptScore W2473105612C126322002 @default.
• W2473105612 hasConceptScore W2473105612C141071460 @default.
• W2473105612 hasConceptScore W2473105612C168563851 @default.
• W2473105612 hasConceptScore W2473105612C203092338 @default.
• W2473105612 hasConceptScore W2473105612C21957315 @default.
• W2473105612 hasConceptScore W2473105612C2776694085 @default.
• W2473105612 hasConceptScore W2473105612C2776755627 @default.
• W2473105612 hasConceptScore W2473105612C2777938653 @default.
• W2473105612 hasConceptScore W2473105612C2778461978 @default.
• W2473105612 hasConceptScore W2473105612C2779263901 @default.
• W2473105612 hasConceptScore W2473105612C2779709957 @default.
• W2473105612 hasConceptScore W2473105612C71924100 @default.
• W2473105612 hasConceptScore W2473105612C90924648 @default.
• W2473105612 hasIssue "21" @default.
• W2473105612 hasLocation W24731056121 @default.
• W2473105612 hasOpenAccess W2473105612 @default.
• W2473105612 hasPrimaryLocation W24731056121 @default.
• W2473105612 hasRelatedWork W2015931113 @default.
• W2473105612 hasRelatedWork W2111286556 @default.
• W2473105612 hasRelatedWork W2120227202 @default.
• W2473105612 hasRelatedWork W2393732692 @default.
• W2473105612 hasRelatedWork W2427404340 @default.
• W2473105612 hasRelatedWork W2439278013 @default.
• W2473105612 hasRelatedWork W2473105612 @default.
• W2473105612 hasRelatedWork W2558080603 @default.
• W2473105612 hasRelatedWork W2883739273 @default.
• W2473105612 hasRelatedWork W2046728322 @default.
• W2473105612 hasVolume "122" @default.
• W2473105612 isParatext "false" @default.
• W2473105612 isRetracted "false" @default.
• W2473105612 magId "2473105612" @default.
• W2473105612 workType "article" @default.